3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
3
Warts
1
Recurrence
1
Pneumonia, Pneumococcal
1
Pneumococcal Infections
1
Neoplasms
1
Multiple Myeloma
1
Immunologic Deficiency Syndromes
1
Hematologic Neoplasms
1
Febrile Neutropenia
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Condylomata Acuminata
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
Vaccines, Synthetic
10
Papillomavirus Vaccines
6
Vaccines
5
Imiquimod
4
Trichloroacetic Acid
3
Gels
3
green tea extract polyphenone E
2
Podophyllin
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Ethanol
2
Duration of Therapy
2
Cryotherapy
2
Cantharidin
2
ranpirnase
1
polyphenon E
1
nanocurcumin
1
human papillomavirus vaccine, L1 type 16, 18
1
hecolin
1
berdazimer sodium
1
Zinc
1
Viusid
1
Vaccination
1
VP-102
1
Tuberculin
1
Therapies, Investigational
1
Tea
1
PRA1 protein, Candida albicans
1
Omiganan
1
Ointments
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Condylomata Acuminata
×
Vaccination
×
Clear all
NCT03296397
2018-02-27
CONDYVAC
Assistance Publique - Hôpitaux de Paris
Phase 3
Unknown
300 enrolled